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Objective: To assess the effectiveness and safety of sodium selenite in treatment of patients with Kashin-
Beck disease (KBD).
Methods:We searched for all publications between January 1966 and October 2011 using seven electronic
databases. All randomized controlled trials (RCTs) assessing the effects of sodium selenite on KBD vs no
treatment or placebo were included. For dichotomous data, odds ratios (OR) and 95% conﬁdence intervals
(CI) were estimated according to the intention-to-treat principles. For continuous data, mean difference
(MD) was used for outcomes pooled on the same scale.
Results: A total of 10 RCTs involving 2244 patients were included. The methodological quality of the
included studies was low. When comparing the outcome of sodium selenite treatment group vs the
control group, the OR of repairing rate of metaphyseal lesions was 5.63 (95% CI: 3.67e8.63) and repairing
rate at the distal end of phalanges was 2.98 (95% CI: 1.32e6.70) based on X-ray assessment, which was
statistically signiﬁcant difference in favour of sodium selenite. In one RCT which reported data on clinical
improvement, no statistically signiﬁcant difference was observed in the treatment vs control group (OR
1.50, 95% CI: 0.43e5.30). Se content in hair was (MD 0.11, 95% CI: 0.09e0.13) which was statistically
signiﬁcant higher in selenium group.
Conclusions: Current evidence suggests that sodium selenite is more effective than placebo or no
treatment in patients with KBD. However, the evidence was limited by potential biases; thus, further
high quality large-scale RCTs are still needed to evaluate the short term and long term effects of
selenium.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Kashin-Beck disease (KBD) is a chronic, endemic, degenerative
osteoarthropathy with severe skeletal deformation and
dwarﬁsm1e3. It is endemic to certain areas of South-Eastern Siberia
to North China, North Korea, Central China and Tibet4,5. A report
published by the Chinese Ministry of Health in 2008 estimated
a population of 105.28 million people living in 366 counties within
the KBD regions, and approximately 714.8 thousands of those
people were found to be affected with KBD. Overall, there are about
2.5 million people diagnosed with KBD in China, Russia and North
Korea6 Most clinical manifestations of the joints become apparent: D. Birong, Department of
, Guoxuexiang 37, Chengdu,
s Research Society International. Pduring childhood up to the age of 25 years. Affected individuals
present with joint destruction leading to recurrent and commonly
bilateral joint pain, movement restriction, and joint enlargement.
Although most commonly seen in adults and often the group more
severely affected, the worst forms of this disease tend to start in
childhood, which may lead to dwarﬁsm1,7. The resulting disability
causes an important human and socioeconomic burden to both
affected children and adults.
From the different hypotheses regarding etiological factors, four
factors have been convincingly associated with the disease: sele-
nium deﬁciency, grain contamination with mycotoxin-producing
fungi, water pollution with organic material, and fulvic acid.
However, none of the proposed explanations are entirely satisfac-
tory; thus, it appears that KBD has a multifactorial origin8,9.
So far, only palliative measures exist for treatment of KBD.
Successful surgical treatments to correct joint defects have been
reported by Chinese and Russian orthopaedists10e12. Recently,
physical therapy aimed at increasing mobility and functioning hasublished by Elsevier Ltd. All rights reserved.
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steroidal antiinﬂammatory drugs for pain relief.
Selenium supplements have been given in some highly endemic
areas for a long time. A meta-analysis including ﬁve randomised
control trials (RCTs) and 10 non-RCTs assessed the efﬁcacy of
selenium supplementation for prevention of KBD in children. The
odd ratios (OR) and number needed to treat (NNT) favoured sele-
nium supplement for prevention of KBD in children14. Some clinical
trials using selenium for treatment of KBD have also been carried
out. However, there is no systematic review evaluating the effects
of selenium treatment for patients that are already affected with
KBD disease. The aim of this systematic review was to synthesize
the results from RCTs to assess the effectiveness and safety of
sodium selenite in treatment of patients with KBD.
Materials and methods
Search strategy and eligibility criteria
We searched, without language restrictions, for all publications
between January 1966 and October 2011 using electronic data-
bases, which included Medline, Embase, Database of Abstracts of
Reviews of Effects, the Cochrane Central Register of Controlled
Trials, the Cochrane Database of Systematic Reviews, The Chinese
Biomedical Database, Chinese National Knowledge Infrastructure,
Chinese Science and Technique Journals Database, and Wan Fang
database. The followingMeSH and freewords were used during the
search: “Kashin-Beck disease”, “big bone disease”, “endemic osteo-
arthritis”, “Urov disease” and “selenium”, “Sodium selenite”, and
“Se”. We also searched the references of review cited for additional
articles that were missed by the computerized database search.
Conference proceedings were checked for any relevant trials, and
authors were contacted for details of unpublished and ongoing trials.Fig. 1. Flow chart of studWe included all RCTs that used sodium selenite alone vs no
treatment or placebo, without age restrictions. Studies that were
excluded consisted of: (1) no placebo or control group, (2) use of
other types of selenium supplements (eg., selenium salt), and (3)
use of sodium selenite in combination with other treatments (eg.,
vitamin E, vitamin C or both). Studies reporting mixed groups of
participants (e.g., participants with and without KBD) were
included only if the therapeutic effect data could be identiﬁed and
extracted separately.
Data extraction
Data was extracted independently by two reviewers using
a standard data extraction form; discrepancies were settled by
discussion. The data extraction form included title, setting, country
of origin, demographics, interventions (dosage, route of adminis-
tration and duration of treatment), sample size and outcomes. The
primary outcomewas repairing rate of metaphyseal lesions and the
distal end of phalanges in hands on X-ray ﬁlms as well as clinical
improvement. The secondary outcomes were Se contents in hair
and adverse effects.
We assessed the methodological quality of each study using
a four-item checklist: (1) reporting of a randomization method, (2)
allocation concealment, (3) investigator blinding for assessment of
outcomes, and (4) completeness of follow-up. The criteria were
drawn from the Cochrane Collaboration tool for assessing risk of
bias15, and the descriptions provided by Wu and Liu16.
Statistical analysis
For dichotomous data (e.g., improvement of metaphyseal lesions
and the distal end of phalanges in hands on X-ray ﬁlms), OR and
95% conﬁdence intervals (CI) were estimated according to they selection process.
Table II
Methodological quality of included RCTs
Study Generation
of random
sequence
Allocation
concealment
Blinding
method
Loss to
follow-up
ITT
YSSG 198217 UC NM Double-blind No Yes
Cui 198418 UC NM Double-blind >20% Not used
Niu 198419 UC NM Double-blind >20% Not used
Guo 198520 UC NM Not Used >20% Not used
Niu 198621 UC NM Double-blind No Yes
Wu 198622 UC NM Double-blind <20% Not used
Deng 198823 UC NM UC UC Not used
Niu 199024 UC NM Single-blind No Yes
Moreno-
Reyes 200325
UC NM Double-blind <20% Not used
Cai 200526 UC NM Not Used No Yes
YSSG¼ Yongshou scientiﬁc survey group of KBD, UC¼ unclear, NM¼ not
mentioned. ITT¼ intention-to-treat.
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contents in hair), the mean difference (MD) was used for outcomes
pooled on the same scale.
Numbers and characteristics of the studies that suggested
a feasible inclusion into the meta-analysis were assessed for
heterogeneity using the Chi2 test with P< 0.1. In addition, I2 was
used to estimate the total variation due to heterogeneity across
studies. Value of I2< 25% was regarded as low heterogeneity and,
a ﬁxed effect model for meta-analysis was used. Value of I2 25%w
75% were regarded as moderate heterogeneity, and a random
effects model was applied. Value of I2>75% represented a high
level of heterogeneity. In this case, meta-analysis was not appro-
priate and thus not performed. Two-tailed tests were used for all
statistical analyses. A P value <0.05 was considered to be statisti-
cally signiﬁcant. All analyses were performedwith ReviewManager
5.0 package.
Sensitivity analysis
After a sufﬁcient number of trials were identiﬁed, a sensitivity
analysis was to be done to assess the robustness of the results for
primary outcome as follows: (1) exclusion of studies with inade-
quate concealment of allocation, (2) exclusion of studies in which
outcome evaluation was not blinded or unclear, (3) exclusion of
studies inwhich loss to follow-up was more than 20%, (4) exclusion
of studies inwhich ITTanalysis was not used or unclear for outcome
evaluation. If enough studies were identiﬁed, funnel plot analysis
were performed to check for publication bias.
Results
Study inclusion and characteristics
Of the 1694 references screened, 10 studies were included in the
ﬁnal analysis. All trials were conducted in China. Nine RCTs were
published in Chinese, and one RCT was published in English (Fig. 1).
Each RCT compared sodium selenite with either no treatment orTable I
Characteristics of included trials
Study Case
number
Age Intervention
I C I C
YSSG 198217 166 159 3w13 3w13 Sodium selenite tablet, 1 mg/week
2 mg/week (11e13 yrs)
Cui 198418 30 30/30 7w19 7w19 Sodium selenite tablet, 1 mg/week
2 mg/week (11e19 yrs)
Niu 198419 121 125 6w13 6w13 Sodium selenite tablet ﬁrst week:
1.0 mg/day (<10 yrs), 2.0 mg/day
1.0 mg/week (<10 yrs), 2.0 mg/we
Guo 198520 50 50/50 5w15 5w15 Sodium selenite tablet, 1 mg/week
2 mg/week (>5 yrs)
Niu 198621 400 390 6w13 6w13 Sodium selenite tablet, 1 mg/week
2 mg/week (>10 yrs)
Wu 198622 171 177 5w16 5w16 Sodium selenite tablet, 1 mg/week
2 mg/week (>10 yrs)
Deng 198823 84 94 2w13 2w13 Sodium selenite, no details
Niu 199024 210 228 6w13 6w13 Sodium selenite, ﬁrst week: 0.5 m
1.0 mg/day (6e10 yrs),
2.0 mg/day (>11 yrs); after: 1.0 m
2.0 mg/month (6e10 yrs), 4.0 mg/
Moreno-
Reyes 200325
113 95 10 0.28 10 0.3 Sodium selenite tablet, 1 mg/week
Cai 200526 40 40 7w13 7w13 Sodium selenite tablet, 2 mg/10 da
3 mg/10 days (11e13 yrs)
yrs¼ years, I¼ intervention, C¼ control, YSSG¼ Yongshou scientiﬁc survey group of KBDa placebo17e26. The main characteristics of the included studies are
presented in Table I.
In total, 2244 individuals were analyzed. The age range of
participants was 2e16 years old. Four studies reported both repair-
ing rate of metaphyseal lesions and the distal end of phalanges in
hands onX-rayﬁlms19,21,23,26, and six studies reported repairing rate
ofmetaphyseal lesions onX-rayﬁlms only17,18,20,22,24,25. Four studies
reported Se contents found in hair19e21,23. Only one study reported
clinical improvement25, and two studies reported adverse
effects17,22. The duration of follow-up of between each RCT varied.
Six studieswere 12 months17e19,21,22,25, one studywas 18 months26,
two studies were 24 months19,21, and one study was 36 months23
after initial treatment.Methodological quality of RCTs
Trial quality was overall low in the included studies. No studies
described adequate methods regarding the sequence of randomi-
zation. No studies reported allocation concealment. Seven studiesControl Follow-up
(mouths)
Outcome
(3e10 yrs), Placebo/week 12 Improvement of metaphyseal
lesions on X-ray
(7e10 yrs), Placebo/week 6w12 Improvement of metaphyseal
lesions on X-ray
(>11 yrs); after:
ek (>11 yrs)
Placebo/week 24 X-ray improvement, Se contents
in hair
(<5 yrs), Placebo/week 12 Improvement of metaphyseal
lesions on X-ray, Se contents
in hair
(<10 yrs), Placebo/week 12w24 X-ray improvement, Se contents
in hair
(<10 yrs), Placebo/week 12 Improvement of metaphyseal
lesions on X-ray
No treatment 36 X-ray improvement, Se contents
in hair
g/day (<5 years),
g/month (<5 yrs),
month (>11 yrs)
Placebo/month 12 Improvement of metaphyseal
lesions on X-ray
Placebo/week 12 X-ray improvement, clinical
improvement
ys (7e10 yrs), No treatment 18 X-ray improvement
.
Fig. 2. Meta-analysis of selenium selenite vs control on repairing rate of metaphyseal lesions on X-ray ﬁlms across different time points.
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studies were double blinded 17e19,22,24,25. Six trials had less than
20% loss to follow-up17,21,22,24e26. A total of four trials used ITT
analysis17,21,24,26. The methodological qualities of included RCTs are
presented in Table II.
Repairing rate of metaphyseal lesions on X-ray ﬁlms
All RCTs reported repairing rate of metaphyseal lesions on X-ray
ﬁlms. Follow-up durations of included RCTs were varied. Figure 2
represents pooled estimates across different time points. We
extracted data to the nearest 12 months to estimate the overall OR.
The OR (random effects model) of X-ray improvement was 5.63Fig. 3. Meta-analysis of selenium selenite vs control on repairing(95% CI: 3.67e8.63) in favour of sodium selenite, which indicated
that repairing rate of metaphyseal lesions on X-ray ﬁlms was
signiﬁcantly higher in selenium selenite group than control group
(Fig. 3).
Repairing rate at the distal end of phalanges in hands on X-ray ﬁlms
Four RCTs reported repairing rate at the distal end of
phalanges in hands on X-ray ﬁlms19,21,23,26. The pooled
OR (random effects model) favouring sodium selenite was
2.98 (95% CI: 1.32e6.70), which indicated a statistically signiﬁ-
cant difference in repairing rate in favour of sodium selenite
(Fig. 4).rate of metaphyseal lesions on X-ray ﬁlms about 12 months.
Fig. 4. Meta-analysis of selenium selenite vs control on repairing rate at the distal end of phalanges in hands on X-ray ﬁlms.
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One RCT reported data on clinical improvement25. A slightly
higher clinical improvement was reported in sodium selenite
group; however, the result was not statistically signiﬁcant (OR 1.50,
95% CI: 0.43e5.30).
Selenium contents in hair
Four studies reported selenium contents in hair19e21,23. The
combined MD from the four studies (random effects model) was
0.11 (95% CI 0.09e0.13). This was statistically signiﬁcant in
favour of selenium supplementation, which showed that sodium
selenite supplement can raise selenium contents found in hair
(Fig. 5).
Sensitivity analysis
Estimates of effect comparing sodium selenite with placebo
depended, to some extent, on the quality of the trials. Allocation
concealment was unclear in all included studies, and therefore
this analysis was not undertaken. Sensitivity analysis was to be
done as follows: (1) exclusion of studies in which outcome
evaluation was not blinded or unclear, (2) exclusion of studies in
which loss to follow-up was more than 20%, (3) exclusion of
studies in which ITT analysis was not used or unclear for primary
outcome evaluation. After doing this, all outcomes were still
found to have a statistically signiﬁcant difference in efﬁcacy
between sodium selenite and controls. Figure 6, showed the
meta-analyses of repairing rate of metaphyseal lesions and the
distal end of phalanges in hands on X-ray ﬁlms from sensitivity
analyses.
Adverse events
Two RCTs discussed the safety of selenium supplementa-
tion19,24. One trial mentioned that “some participants had nauseaFig. 5. Meta-analysis of selenium selenite vand vomiting at the beginning of the trial”24, but did not present
further details. The other trials described no observable adverse
events19.Discussion
The results of our review suggest that sodium selenite was
more effective than placebo or control groups for the treatment
of KBD. Sodium selenite were associated with higher repairing
rate of metaphyseal lesions and the distal end of phalanges in
hands on X-ray ﬁlms, as well as increased selenium contents in
hair. However, the results of one RCT showed no signiﬁcant
difference in clinical improvement between sodium selenite and
placebo.
Selenium plays an important role in the biological pathways
by forming selenoproteins. These include glutathione peroxidase
(one of the best characterized selenoproteins, which acts as
a catalyst in the breakdown of a wide range of organic and
inorganic peroxides, and protects cells against oxidative stress)
and iodothyronine deiodinase (a crucial compound in the
generation of the active hormone T3). Since selenium is
a required molecule for the functioning of glutathione peroxi-
dase, it therefore also plays an indirect role in the control of T4
synthesis27.
Selenium deﬁciency has been suggested as a risk factor for
KBD. KBD often occurs in areas with lower environmental sele-
nium concentrations. Generally, total soil selenium concentra-
tions are typically within the range of 0.01e2.0 mg/kg, with an
overall mean of 0.4 mg/kg28. Most of the inhabitants living in
areas with KBD have a low selenium nutritive status, which is
reﬂected by low selenium contents in their hair, blood and
urine29. Our results are in agreement with previous studies. One
meta-analysis demonstrated the beneﬁts of selenium supple-
mentation for the primary prevention of KBD in children14. Some
trials have shown that selenium-rich salts were associated
with improvement of X-ray changes on metaphyseal lesions
compared to the control group30,31. Thus, spraying selenium ontos control for selenium contents in hair.
Fig. 6. (a) Sensitivity analysis for repairing rate of metaphyseal lesions on X-ray ﬁlms. (b) Sensitivity analysis for repairing rate at the distal end of phalanges in hands on X-ray ﬁlms.
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also help improve the pathological changes of phalangeal
metaphyses in KBD children, as well as reduce the prevalence of
KBD32,33.
However, the efﬁcacy of selenium supplements in the
prevention and treatment of KBD is controversial. In a cross-
sectional community survey in Tibet, Moreno-Reyes et al.
found no association between individual selenium status and
KBD, whereas iodine deﬁciency was a risk factor34. In our
systematic review, no improvements in clinical symptoms were
found in association with sodium selenite use. The negative
ﬁndings of this one RCT included in our study25 should, however,
be interpreted with caution. First, the sample size of this trial
was too small. Only 113 participants were included in the
sodium selenite group and 95 participants in the placebo group.
Secondly, the lack of objective adjudication in classifying clinical
symptoms also needs to be recognized. Clinical improvement
was loosely deﬁned as “an improvement of at least one stage on
the scale of clinical severity.” Lastly, this RCT was conducted in
Tibet. Selenium and iodine are both deﬁcient in the Tibet diet.
Because selenium supplementation in iodine-deﬁcient subjects
can aggravate symptoms of hypothyroidism35, iodine deﬁciency
in all subjects was ﬁrst corrected before beginning the study. As
we know, KBD seems unlikely to be due to only one agent or
cause. Other genetic and environmental factors may confer
either a relatively protective effect or accelerate the disease. In
animal experiments, growth retardation was observed in rats fed
with a low selenium diet36, and impaired bone development was
observed with an iodine deﬁcient diet37. Iodine deﬁciency with
low selenium was suggested as environmental risk factors
associated with KBD. We do not exclude the possibility that
selenium supplementation may have no additional effect on
bone growth after iodine deﬁciency was corrected for. However,
iodine supplementation served as a confounding factor in
this RCT.
Overall, the methodological quality of the included trials was
low. Selection and detection bias may have been encountered in
these RCTs. The lack of disclosure of the method of randomization
and of allocation concealment in all the included trials is con-
cerning. The effects found may be overestimated by up to 30e40%
when allocation concealment is absent38. Among 10 trials, seven
RCTs utilized a blinded design17e19,21,22,24,25. Six studies reported
those who were double blinded in the study17e19,22,24,25. Only ﬁve
trials performed ITT analysis17,18,21,24,26. Withdrawal rates of
subjects were less than 20% in two RCTs22,25, four RCTs reported no
losses to follow-up17,21,24,26.
Potential limitations to this review exist. First, the duration of
sodium selenite use varied greatly. Duration of follow-up varied
from 12 months to 3 years. This heterogeneity can be eliminated
by subgroup analysis using different time durations. However,
the most favourable duration of treatment time is still uncertain
for KBD. Conferring to other RCT about osteoarthritis, 3 years of
treatment duration may be suitable for observing X-ray repairing
changes of KBD. Second, the sample sizes of our included RCTs
were all small. Sample size calculations were not mentioned in
any of the studies. Despite our exhaustive search, only 10 RCTs
conducted in China were included in this review. North Korea
and Russia also have a high incidence of KBD; some trials may
have been published in local journals that were missed in our
search. Third, the heterogeneity in this meta-analysis was
somewhat high, which could be explained by a lack of conceal-
ment of allocation, failure to perform an ITT analysis, small
sample sizes of the studies included and differences between
different preparations of selenium. Finally, the age range of
participants in our review was 2e16 years old. Therefore, theeffectiveness of selenium supplementation for adults cannot be
estimated.Conclusions
Implications for practice
Based on this systematic review, it appears that sodium selenite
wasmore effective than placebo or control groups for the treatment
of KBD in children. Nevertheless, the evidence may be limited by
potential biases; thus, further evidence from higher quality trials is
necessary.Implications for research
Well-designed RCTs are needed to conﬁrm the available
evidence. The following features should be addressed in further
studies:
(1) Larger sample RCTs with a calculated sample size;
(2) Detailed reporting of the methods of randomisation;
(3) Adequate implementation of allocation concealment;
(4) Application and clear descriptions of blinding methods, which
should be applied to participants and X-ray radiologists;
(5) Adverse events critically assessed by standardized reporting;
(6) Longer duration of treatment (e.g., 3 years);
(7) Detailed reporting of the reasons to losses of follow-up;
(8) Application of ITT analysis.Contributors
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